Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma.
Acta Gastroenterol Belg
; 77(4): 386-8, 2014 Dec.
Article
em En
| MEDLINE
| ID: mdl-25682626
ABSTRACT
The multi-kinase inhibitor sorafenib still remains the only approved agent for advanced HCC. Its benefits typically involve disease stabilisation, whereas an induction of response is rare. We report a series of five cases with extraordinary response to sorafenib. For two patients complete response to sorafenib was reported with a recurrence-free survival of 51 and 21 months. In another HCC patient pretreated with transarterial chemoembolisation (TACE) sorafenib treatment resulted in a complete response with no evidence of disease 18 months after first diagnosis. In patient 4 with unresectable HCC and sorafenib therapy secondary resectability and subsequent liver transplantation was achieved. Patient 5 had stabilised disease for 48 months after TACE and sorafenib treatment. Sorafenib may be very potent in individual patients. Excellent interdisciplinary strategies are required to achieve best results. There is an urgent need of predictive biomarkers to identify HCC patients that will benefit the most.
Buscar no Google
Base de dados:
MEDLINE
Métodos Terapêuticos e Terapias MTCI:
Terapias_biologicas
/
Aromoterapia
Assunto principal:
Compostos de Fenilureia
/
Niacinamida
/
Carcinoma Hepatocelular
/
Neoplasias Hepáticas
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Acta Gastroenterol Belg
Ano de publicação:
2014
Tipo de documento:
Article